SecBot SecBot

ATRA drug pipeline

$6.40
−16.9% 1-day · Nov 16
Next catalyst
Mar 31, 2027
tabelecleucel PDUFA date · in 134 days
Typical move on FDA news
±57.0%
1-day, median of 7 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Mar 31, 2027134d
    tabelecleucel
    PDUFA date · Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)

Drugs

soonest catalyst first
● neutral
Impact
PhaseFiled/PDUFA (BLA resubmitted and accepted by FDA)
Time to marketThe FDA PDUFA target action date is March 31, 2027, approximately 4.5 months from today. If approved, launch in the US would follow shortly after.

tabelecleucel Updated Nov 14

134days
Next catalyst
PDUFA date · Mar 31, 2027 · Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)
What to watch

The next hard catalyst is the FDA PDUFA target action date of March 31, 2027 for the BLA resubmission of tabelecleucel in EBV+ PTLD. Approval would make it the first FDA-approved therapy for this ultra-rare condition and could drive significant upside from the current ~$7.70 share price (analyst mean target $13.67). A third CRL would likely be devastating for the stock given the company's narrow focus on this asset.

Bull case
  • Tabelecleucel would be the first FDA-approved treatment for EBV+ PTLD, an ultra-rare and life-threatening complication of organ or stem-cell transplant with no approved US therapy.
  • The FDA accepted the resubmitted BLA in October 2026 and assigned a PDUFA date of March 31, 2027, signaling the agency found the new data package sufficient for review.
  • The drug is already approved in Europe (marketed as Ebvallo) and generated $1.22M in Q3 2026 commercialization revenue, providing some real-world commercial validation.
Bear case
  • Two prior Complete Response Letters (most recently Jan 9, 2026, which triggered a ~66% single-day crash from $17.44 to $5.88) underscore the FDA's shifting and unpredictable stance on the ALLELE trial data.
  • The FDA has twice deemed the Phase 3 ALLELE trial inadequate to support approval, and the third attempt relies on the same trial with additional supportive data and manufacturing evidence; the risk of a third CRL remains high.
  • Atara is a net cash-burning company with only $1.22M in quarterly commercialization revenue (from Europe), and its market cap/survival depends almost entirely on this single FDA decision.

Past FDA events & how the stock moved

7 events
DateDrugEvent1 day5 days
Jan 10, 2026tabelecleucelPDUFA decision−57.0%−66.8%
Jan 10, 2026tabelecleucelBLA filed−57.0%−66.8%
Jan 10, 2026tabelecleucelPriority review−57.0%−66.8%
Jan 9, 2026tabelecleucelComplete response letter−66.3%−74.0%
Jan 1, 2026tabelecleucelComplete response letter−1.8%−3.6%
Oct 1, 2025tabelecleucelBLA filed+1.1%+10.6%
Oct 1, 2025tabelecleucelPriority review+1.1%+10.6%